Acetylon Pharmaceuticals, Inc. is a biotechnology startup founded in 2008 and is focused on developing next-generation, selective histone deacetylase (HDAC) enzyme inhibitors with potential applications across various areas including hematologic and solid tumor cancers, inflammatory diseases, neurodegenerative diseases, genetic diseases, and infectious diseases. Acetylon's technology is licensed from Harvard University and the Dana Farber Cancer Center.
The company successfully raised $7.25M in a Series A financing round which involved private investors including The Kraft Group in July 2009. Additionally, Acetylon received a substantial $100.00M Private Equity Round investment from Celgene on 29 July 2013.
With an investment from a significant player like Celgene and an innovative approach to developing treatments for a wide range of diseases, Acetylon Pharmaceuticals holds strong potential for growth and impact in the biotechnology and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Private Equity Round | $100.00M | 1 |
|
29 Jul 2013 |
| Private Equity Round | $15.00M | 1 |
|
09 Feb 2012 |
| Series B | $14.60M | - | 29 Jun 2011 | |
| Series B | $12.40M | - | 22 Feb 2011 | |
| Series A | $2.00M | - | 08 Jan 2010 |
No recent news or press coverage available for Acetylon Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
